#China #Shanghai #Frost & Sullivan #WuXi AppTec #CRDMO

WuXi AppTec's Remarkable Achievement

In an impressive display of consistency and dedication to excellence, WuXi AppTec has once again been honored with Frost & Sullivan's coveted Global Company of the Year recognition in the Contract Research, Development, and Manufacturing Organization (CRDMO) industry. This accolade marks the tenth consecutive year that WuXi AppTec has received this prestigious award, underscoring its commitment to supporting the pharmaceutical and life sciences sectors.

Frost & Sullivan's recognition of WuXi AppTec comes as no surprise, given the company’s integrated CRDMO model. This approach enables WuXi AppTec to assist clients throughout the entire drug development process—from the initial stages of discovery to the eventual commercial manufacturing of pharmaceutical products. The firm’s ability to deliver consistent operational excellence across various global markets has solidified its reputation as a leader in the industry.

Unmesh Lal, Vice President of Healthcare and Life Sciences at Frost & Sullivan, praised WuXi AppTec for its strong adaptation to the evolving needs of its customers. He noted that the company’s strategies and operational frameworks effectively support biopharmaceutical innovators globally. Lal emphasized, “WuXi AppTec distinguishes itself through its strong focus on evolving customer needs, reinforcing its position as a trusted partner.”

Dr. Ge Li, the Chairman and CEO of WuXi AppTec, expressed profound gratitude for this recognition. He stated, “We are honored that Frost & Sullivan has once again recognized what our teams deliver every day for customers. As a dedicated enabler of the pharmaceutical industry, we remain committed to our CRDMO strategy and to helping customers around the world bring life-changing therapies to patients faster.”

Frost & Sullivan’s Company of the Year award is their highest honor, presented to organizations that showcase visionary innovation, market-leading performance, and unparalleled customer service. This acknowledgment not only reflects the efforts of WuXi AppTec's teams but also highlights the company’s role in advancing healthcare solutions that benefit patients worldwide.

About WuXi AppTec:
WuXi AppTec positions itself as a vital partner in the pharmaceutical and life sciences sectors, delivering research and manufacturing services that accelerate healthcare innovations. Operating across Asia, Europe, and North America, WuXi AppTec provides an end-to-end service platform that aims to expedite the availability of new treatments. The firm collaborates with partners across more than 30 countries, contributing to the development of breakthroughs in medicine and patient care. With a vision that every drug can be made and every disease can be treated, WuXi AppTec continues to push boundaries and transform healthcare on a global scale. For more information on their services and initiatives, visit WuXi AppTec's website.

In summary, WuXi AppTec's reaffirmation as a leader in the CRDMO sector solidifies its mission of enabling healthcare innovations and its unwavering commitment to supporting the biopharmaceutical industry, ultimately striving to bring better health to patients around the world.